Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, Anagnostou V, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Lin CT, Feller-Kopman D, Lerner AD, Lee H, Shafiq M, Yarmus L, Lipson EJ, Soloski M, Brahmer JR, Danoff SK, D'Alessio F.

J Clin Invest. 2019 Jul 16;130. pii: 128654. doi: 10.1172/JCI128654.

2.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
3.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
4.

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J.

Clin Lung Cancer. 2019 Jul;20(4):e470-e479. doi: 10.1016/j.cllc.2019.02.018. Epub 2019 Mar 28.

PMID:
31031204
5.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

6.

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Forde PM, Scherpereel A, Tsao AS.

Curr Treat Options Oncol. 2019 Feb 14;20(2):18. doi: 10.1007/s11864-019-0613-x. Review.

PMID:
30762130
7.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

8.

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, Chaft J, Forde PM, Jones DR, Broderick SR.

J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276. doi: 10.1016/j.jtcvs.2018.11.124. Epub 2018 Dec 13.

PMID:
30718052
9.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE.

Lung Cancer. 2019 Feb;128:74-90. doi: 10.1016/j.lungcan.2018.12.003. Epub 2018 Dec 6.

PMID:
30642457
10.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H.

Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.

11.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.

12.

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.

Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D'Alessio F, Danoff SK, Naidoo J.

J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.

PMID:
30503891
13.

PD-1 Blockade in Early-Stage Lung Cancer.

Rosner S, Reuss JE, Forde PM.

Annu Rev Med. 2019 Jan 27;70:425-435. doi: 10.1146/annurev-med-050217-025205. Epub 2018 Oct 24.

PMID:
30355264
14.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

15.

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J.

J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.

PMID:
30267842
16.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Pardoll DM.

N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251. No abstract available.

PMID:
30157404
17.

Lung and Thymic Carcinoids.

Hann CL, Forde PM.

Endocrinol Metab Clin North Am. 2018 Sep;47(3):699-709. doi: 10.1016/j.ecl.2018.04.011. Review.

PMID:
30098725
18.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.

19.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.

20.

Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.

Bulbul A, Forde PM, Murtuza A, Woodward B, Yang H, Bastian I, Ferguson PK, Lopez-Diaz F, Ettinger DS, Husain H.

Oncology (Williston Park). 2018 Apr 15;32(4):156-63. Review.

21.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

22.

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.

Yeh J, Marrone KA, Forde PM.

J Thorac Dis. 2018 Feb;10(Suppl 3):S451-S459. doi: 10.21037/jtd.2018.01.109. Review.

23.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

PMID:
29573850
24.

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL, Ettinger DS.

Oncologist. 2018 Jul;23(7):859-865. doi: 10.1634/theoncologist.2017-0465. Epub 2018 Feb 27.

25.

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.

PMID:
29485071
26.

Clinical mutational profiling of 1006 lung cancers by next generation sequencing.

Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM, Lin MT.

Oncotarget. 2017 May 20;8(57):96684-96696. doi: 10.18632/oncotarget.18042. eCollection 2017 Nov 14.

27.

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.

Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066.

28.

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM.

Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065.

29.

Cancer Immunotherapy in Older Patients.

Marrone KA, Forde PM.

Cancer J. 2017 Jul/Aug;23(4):219-222. doi: 10.1097/PPO.0000000000000268. Review.

PMID:
28731944
30.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

31.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

32.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

33.

Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet need.

Marrone KA, Forde PM.

Transl Lung Cancer Res. 2015 Dec;4(6):801-3. doi: 10.3978/j.issn.2218-6751.2015.05.04. No abstract available.

34.

Managing acquired resistance in EGFR-mutated non-small cell lung cancer.

Forde PM, Ettinger DS.

Clin Adv Hematol Oncol. 2015 Aug;13(8):528-32. Review.

PMID:
26351816
35.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.

Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Review.

36.

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.

Kelly RJ, Forde PM, Elnahal SM, Forastiere AA, Rosner GL, Smith TJ.

J Oncol Pract. 2015 Jul;11(4):308-12. doi: 10.1200/JOP.2015.003780. Epub 2015 May 26.

37.

Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT.

Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, Meyer CF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC, Park BH.

J Clin Oncol. 2016 Jan 20;34(3):e13-6. doi: 10.1200/JCO.2013.51.6633. Epub 2014 May 27. No abstract available.

PMID:
24868028
38.

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR.

Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Review.

39.

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.

Forde PM, Brahmer JR, Kelly RJ.

Clin Cancer Res. 2014 May 1;20(9):2244-8. doi: 10.1158/1078-0432.CCR-13-2088. Epub 2014 Mar 18. Review.

40.

Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.

Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, Brahmer JR, Kelly RJ.

J Thorac Oncol. 2014 Mar;9(3):414-8. doi: 10.1097/JTO.0000000000000065.

41.

New strategies in lung cancer: translating immunotherapy into clinical practice.

Forde PM, Kelly RJ, Brahmer JR.

Clin Cancer Res. 2014 Mar 1;20(5):1067-73. doi: 10.1158/1078-0432.CCR-13-0731. Epub 2014 Jan 27. Review.

42.

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2014 Mar;20(3):314-8. doi: 10.1016/j.bbmt.2013.11.020. Epub 2013 Dec 1.

43.

What lies within: novel strategies in immunotherapy for non-small cell lung cancer.

Forde PM, Reiss KA, Zeidan AM, Brahmer JR.

Oncologist. 2013;18(11):1203-13. doi: 10.1634/theoncologist.2013-0171. Epub 2013 Oct 8. Review.

44.

Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers.

Zeidan AM, Wellman J, Forde PM, Bolaños-Meade J, Streiff MB.

J Thromb Thrombolysis. 2014 May;37(4):524-6. doi: 10.1007/s11239-013-1002-0. No abstract available.

45.

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

Forde PM, Kelly RJ.

Oncologist. 2013;18(7):823-32. doi: 10.1634/theoncologist.2013-0130. Epub 2013 Jul 12.

46.

Abiraterone for the Treatment of Advanced Prostate Cancer.

Forde PM, Antonarakis ES.

Int J Target Ther Cancer. 2012 Sep 1;1(3):40-42.

47.

Tumor lysis syndrome in limited-stage small-cell lung cancer.

Boikos SA, Forde PM, Chatterjee S, Hann CL.

J Thorac Oncol. 2013 Jul;8(7):e61-2. doi: 10.1097/JTO.0b013e318286bb3b. No abstract available.

48.

Targeted therapy for non-small-cell lung cancer: past, present and future.

Forde PM, Ettinger DS.

Expert Rev Anticancer Ther. 2013 Jun;13(6):745-58. doi: 10.1586/era.13.47. Review.

49.

Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.

Forde PM, Kelly RJ.

J Thorac Oncol. 2013 Jun;8(6):673-84. doi: 10.1097/JTO.0b013e31828b5172.

50.

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.

Hourigan CS, Forde PM, Ambinder RF, Gladstone DE.

Leuk Lymphoma. 2013 Nov;54(11):2563-4. doi: 10.3109/10428194.2013.780289. Epub 2013 Apr 19. No abstract available.

Supplemental Content

Loading ...
Support Center